2型糖尿病患者吸烟与代谢相关脂肪性肝病关系的研究-现代医学

2型糖尿病患者吸烟与代谢相关脂肪性肝病关系的研究

单位：东南大学附属中大医院内分泌科, 江苏南京 210009

分类号：R587

出版年·卷·期（页码）：2024·52·第五期（759-763）

摘要：

目的：探讨2型糖尿病(T2DM)患者中吸烟与代谢相关脂肪性肝病(MAFLD)之间的关系。方法：选取2020年12月至2023年3月在东南大学附属中大医院内分泌科住院的1 466例T2DM患者为研究对象。收集患者的一般资料和实验室指标，并使用脂肪肝指数(FLI)评估肝脏脂肪积累，将患者分为MAFLD组和非MAFLD组进行比较。采用Logistic回归分析探讨吸烟与MAFLD的关系。结果：MAFLD组的患者男性占比更多，年龄更小，病程也更短；其尿酸、甘油三酯和总胆固醇血清水平更高，高密度脂蛋白水平较低。MAFLD组吸烟患者占比更高(42.1% vs. 28.9%，P＜0.001)。在校正性别、年龄、病程、糖化血红蛋白、体质指数(BMI)后，吸烟仍是T2DM患者发生MAFLD的危险因素。结论：吸烟是T2DM患者发生MAFLD的危险因素。

Objective: To investigate the association between smoking and metabolism-associated fatty liver disease (MAFLD) in patients with type 2 diabetes mellitus (T2DM). Methods: A total of 1 466 inpatients with T2DM from Department of Endocrinology at Zhongda Hospital were enrolled in this study. Demographic characteristics and laboratory data were collected. Hepatic fat accumulation was assessed by fatty liver index (FLI). According to FLI, patients were categorized into MAFLD and non-MAFLD groups. We analysed the association between smoking and MAFLD with multivariable Logistic regression. Results: Patients in MAFLD group were predominantly male, younger, and had a shorter disease duration. Serum levels of uric acid, triglycerides, and total cholesterol were higher and level of high-density lipoproteins was lower in those with MAFLD. Prevalence of smokers was higher in MAFLD group (42.1% vs. 28.9%, P<0.001). After adjusting for gender, age, disease duration, glycemic control, and BMI, smoking was still a significant risk factor for MAFLD in patients with T2DM. Conclusion: Smoking was a risk factor in the development of MAFLD in participants with T2DM.

参考文献：

[1] SCHAFFNER F,THALER H.Nonalcoholic fatty liver disease[J].Progress in liver diseases,1986,8:283-298.
[2] ADAMS L A,ANSTEE Q M,TILG H,et al.Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J].Gut,2017,66:1138-1153
[3] ESLAM M,NEWSOME P N,SARIN S K,et al.A new definition for metabolic dysfunction-associated fatty liver disease:an international expert consensus statement[J].J Hepatol,2020,73(1):202-209.
[4] YOUNOSSI Z M,GOLABI P,DE AVILA L,et al.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:a systematic review and meta-analysis[J].J Hepatol,2019,71(4):793-801.
[5] ZEIN C O.Clearing the smoke in chronic liver diseases[J].Hepatology (Baltimore,Md) 2010; 51(5):1487-1490.
[6] ZEIN C O,BEATTY K,POST A B,et al.Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis:a cross validated retrospective assessment[J].Hepatology,2006,44(6):1564-1571.
[7] PETRICK J L,CAMPBELL P T,KOSHIOL J,et al.Tobacco,alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma:the liver cancer pooling project[J].Br J Cancer,2018,118(7):1005-1012.
[8] JANG Y S,JOO H J,PARK Y S,et al.Association between smoking cessation and non-alcoholic fatty liver disease using NAFLD liver fat score[J].Front Public Health,2023,11:1015919.
[9] American Diabetes Association.2.Classification and diagnosis of diabetes:standards of medical care in diabetes-2019[J].Diabetes Care,2019,42(Suppl 1):S13-S28.
[10] BEDOGNI G,BELLENTANI S,MIGLIOLI L,et al.The Fatty Liver Index:a simple and accurate predictor of hepatic steatosis in the general population[J].BMC Gastroenterology,2006,6:33.
[11] HUANG T D,BEHAR J,ZEKRY A.Non-alcoholic fatty liver disease:a review of epidemiology,risk factors,diagnosis and management[J].Intern Med J,2020,50(9):1038-1047.
[12] AUBERT L,SANDINO J,GUTIÉRREZSOLÍS E,et al.Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus[J].Nephrol Dial Transplanta,2021,36(5):1-7.
[13] 中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志，2018,38(4):292-344.
[14] BUTT A S,HAMID S,HAIDER Z,et al.Nonalcoholic fatty liver diseases among recently diagnosed patients with Diabetes Mellitus and risk factors[J].Euroasian J Hepatogastroenterol,2019,9(1):9-13.
[15] DEGUISE M O,BARANELLO G,MASTELLA C,et al.Abnormal fatty acid metabolism is a core component of spinal muscular atrophy [J].Ann Clin Trans Neurol,2019,6(8):1519-1532.
[16] JARVIS H,CRAIG D,BARKER R,et al.Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD):a systematic review and meta-analysis of population-based observational studies[J].PLoS,2020,17(4):e1003100.
[17] LIU Z,LI Y H,CUI Z Y,et al.Prevalence of tobacco dependence and associated factors in China:findings from nationwide China Health Literacy Survey during 2018-19[J].Lancet Reg Health West Pac,2022,24:100464.
[18] JUNG H S,CHANG Y,KWON M J,et al.Smoking and the risk of non-alcoholic fatty liver disease:a cohort study[J].Am J Gastroentero,2019,114(3):453-463.
[19] LIU Y,DAI M,BI Y,et al.Active smoking,passive smoking,and risk of nonalcoholic fatty liver disease (NAFLD):a population-based study in China[J].J Epidemiol,2013,23(2):115-121.
[20] ZEIN C O,UNALP A,COLVIN R,et al.Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease[J].J Hepatol,2011,54(4):753-759.
[21] DULAI P S,SINGH S,PATEL J,et al.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:systematic review and meta-analysis[J].Hepatology,2017,65(5):1557-1565.
[22] YUAN H,SHYY J Y,MARTINS-GREEN M.Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1[J].J Hepatol,2009,51(3):535-547.
[23] FRIEDMAN T C,SINHA-HIKIM I,PARVEEN M,et al.Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice[J].Endocrinology,2012,153(12):5809-5820.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录